user

COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE: A DISCRETE EVENT SIMULATION ECONOMIC MODELLING STUDY

被引：2
|
作者：
Men, P. [1 ]
Liu, T. [2 ]
Chu, Y. [3 ]
Zhai, S. [1 ]
机构：
[1] Peking Univ, Hosp 3, Dept Pharm, Beijing, Peoples R China
[2] Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China
[3] Boehringer Ingelheim China Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.497
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB45
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [2] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    [J]. Cost Effectiveness and Resource Allocation, 19
  • [3] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Lars Holger Ehlers
    Mark Lamotte
    Sofia Monteiro
    Susanne Sandgaard
    Pia Holmgaard
    Evan C. Frary
    Niels Ejskjaer
    [J]. Diabetes Therapy, 2021, 12 : 1523 - 1534
  • [4] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Ehlers, Lars Holger
    Lamotte, Mark
    Monteiro, Sofia
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    [J]. DIABETES THERAPY, 2021, 12 (05) : 1523 - 1534
  • [5] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
  • [6] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Vasilis Tsimihodimos
    Viana Diogo
    George Karpouzos
    Giannis Papageorgiou
    Georgia Kourlaba
    [J]. Clinical Drug Investigation, 2021, 41 : 371 - 380
  • [7] Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Gandhi, Pranav K.
    Cragin, Lael
    Brand, Sarah B.
    Pfarr, Egon
    Fahrbach, Kyle
    Ustyugova, Anastasia
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [8] Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Mafalda Ramos
    Volker Foos
    Anastasia Ustyugova
    Nikco Hau
    Pranav Gandhi
    Mark Lamotte
    [J]. Diabetes Therapy, 2019, 10 : 2153 - 2167
  • [9] Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Ramos, Mafalda
    Foos, Volker
    Ustyugova, Anastasia
    Hau, Nikco
    Gandhi, Pranav
    Lamotte, Mark
    [J]. DIABETES THERAPY, 2019, 10 (06) : 2153 - 2167
  • [10] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
    Pawlik, D.
    Wojcik, R.
    Zawodnik, A.
    Kaczor, M. P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
12345